Overall, our study corroborates the anti-inflammatory properties of LRRK2 kinase inhibition in preclinical models of AD- and PD-related neuroinflammation and supports the hypothesis that targeting LRRK2 activity could be protective and beneficial for brain disorders with an inflammatory component. This evidence concerns the gene LRRK2 and Parkinson disease.